Ritonavir (Norvir) Research
- Intranasal and Topical Corticosteroids and Risk of Cushing's Symptoms in HIV Patients on Ritonavir-Based Combinations (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Case Reports of Complications From Ketamine Use in Two MSM on Ritonavir-Based Combinations (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Warfarin and ARVs: Impact of African-American Race and Ritonavir (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Treatment With a Ritonavir-Boosted Protease Inhibitor During Pregnancy Increases Risk of Preterm Delivery (April 10, 2012)
From aidsmap.com
 Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
From TheBody.com
- Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Reyataz/Isentress Combo Spares Norvir and Nukes, but Is Integrase Resistance a Concern? (July 22, 2010)
From AIDSmeds.com
- The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Among Patients on Boosted-PI Regimens, Dose Staggering and Selective Non-Adherence to Ritonavir Is Relatively Common (February 6, 2008)
From TheBodyPRO.com
- Short-Term Ritonavir Exposure Impacts HDL, CD36 and Triglyceride Levels in Healthy Volunteers (February 4, 2008)
Marta Boffito, M.D., Ph.D., discusses her study, which examines the possible role of ritonavir in increasing cardiovascular risk.
From TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
